Study of Light Treatment and Laser Treatment for Melasma

A Randomized, Rater-blinded, Split-face Comparison of the Efficacy of Intense Pulse Light vs. Q-switched Nd:Yag Laser for the Treatment of Melasma.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00509977

Enrollment

Registered

2007-08-01

Start date

2007-04-30

Completion date

2009-09-30

Last updated

2021-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma

Brief summary

The purpose of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

Detailed description

The objective of this study is to determine the efficacy of light treatment and laser treatment for melasma. These treatment options have not been thoroughly explored in the treatment of melasma. By studying the effect of different treatments, a better treatment plan may be developed for people with melasma.

Interventions

PROCEDURELight Treatment

Light treatment applied to half of the face at each study visit

PROCEDURELaser Treatment

Laser treatment applied to half of the face at each study visit

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of melasma lesion measuring at least 4 square centimeters. * Age 18-75 years. * Good health. * Willingness and ability to understand and provide informed consent for participation in the study. * Ability to communicate with the investigator. * Must be willing to forgo other treatment options for melasma during the course of the study.

Exclusion criteria

* Inability to understand the protocol or to give informed consent. * Mental illness. * Under 18 years of age and over 75 years of age. * Laser treatment in the last 6 months before enrollment. * Isotretinoin within the past year. * Lidocaine allergy. * History of herpes simplex viral infection. * Concurrent active disease to facial area (i.e acne). * Bleeding disorder. * History of abnormal wound healing. * History of abnormal scarring.

Design outcomes

Primary

Measure	Time frame
Melasma Area and Severity Index	20 weeks

Secondary

Measure	Time frame
Safety	20 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026